| Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose. | |
| | |
MedLine Citation:
|
PMID: 20630944 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Telmisartan improves glucose and lipid metabolism in rodents. This study evaluated the effect of telmisartan on insulin sensitivity, substrate utilization, selected plasma adipokines and their expressions in subcutaneous adipose tissue (SAT) in metabolic syndrome. DESIGN AND METHODS: Twelve patients with impaired fasting glucose completed the double-blind, randomized, crossover trial. Patients received telmisartan (160 mg/day) or placebo for 3 weeks and vice versa with a 2-week washout period. At the end of each period, a hyperinsulinemic euglycemic clamp (HEC) combined with indirect calorimetry was performed. During HEC (0, 30, and 120 min), plasma levels of adipokines were measured and a needle biopsy (0 and 30 min) of SAT was performed. RESULTS: Fasting plasma glucose was lower after telmisartan compared with placebo (P<0.05). There were no differences in insulin sensitivity and substrate utilization. We found no differences in basal plasma adiponectin, resistin and tumour necrosis factor α (TNFα), but an increase was found in basal leptin, after telmisartan treatment. Insulin-stimulated plasma adiponectin (P<0.05), leptin and resistin (P<0.001) were increased, whereas TNFα was decreased (P<0.05) after telmisartan treatment. Expression of resistin, but not adiponectin, TNFα and leptin was increased after telmisartan treatment. CONCLUSIONS: Despite the decrease in fasting plasma glucose, telmisartan does not improve insulin sensitivity and substrate utilization. Telmisartan increases plasma leptin as well as insulin-stimulated plasma adiponectin, leptin and resistin, and decreases plasma TNFα during HEC. Changes in plasma adipokines cannot be explained by their expressions in SAT. The changes in plasma adipokines might be involved in the metabolic effects of telmisartan in metabolic syndrome. |
| | |
Authors:
|
Petr Wohl; Eva Krusinová; Martin Hill; Simona Kratochvílová; Katerina Zídková; Jan Kopecký; Tomás Neskudla; Michal Pravenec; Marta Klementová; Jana Vrbíková; Pavel Wohl; Petr Mlejnek; Terezie Pelikánová |
Related Documents
:
|
19785634 - Metabolic profiles of fat and glucose differ by gender in healthy 8-year-olds. 16081264 - Modulation of carbohydrate metabolism and peptide hormones by soybean isoflavones and p... 14615274 - Insulin resistance of gluconeogenic pathways in neonatal rats after prenatal ethanol ex... 12679444 - Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after... 17288494 - Management of lithium toxicity. 19785634 - Metabolic profiles of fat and glucose differ by gender in healthy 8-year-olds. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-07-14 |
Journal Detail:
|
Title: European journal of endocrinology / European Federation of Endocrine Societies Volume: 163 ISSN: 1479-683X ISO Abbreviation: Eur. J. Endocrinol. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-17 Completed Date: 2010-10-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9423848 Medline TA: Eur J Endocrinol Country: England |
Other Details:
|
Languages: eng Pagination: 573-83 Citation Subset: IM |
Affiliation:
|
Diabetes Center, Institute for Clinical and Experimental Medicine, Vídenská 1958/4, Prague, Czech Republic. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adipokines
/
blood* Adult Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Benzimidazoles / therapeutic use* Benzoates / therapeutic use* Blood Glucose / drug effects, metabolism Glucose Clamp Technique Glucose Intolerance / blood, drug therapy* Humans Hypoglycemic Agents / therapeutic use* Insulin / therapeutic use* Insulin Resistance / physiology Male Metabolic Syndrome X / blood, drug therapy* Middle Aged |
| Chemical | |
Reg. No./Substance:
|
0/Adipokines; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Benzimidazoles; 0/Benzoates; 0/Blood Glucose; 0/Hypoglycemic Agents; 11061-68-0/Insulin; 144701-48-4/telmisartan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of biostabilization on the release potential and speciation of heavy metals in municipal soli...
Next Document: The activation of membrane targeted CaMK-II in the zebrafish Kupffer's vesicle is required for left-...